Preview | Agreement as Follows: |

Document Preview

Agreement as Follows:

Click "Add to Cart" button to purchase document.
Documents are emailed immediately after purchase.
You can also browse documents by title, category, or company... or click here for help finding documents.

Title:

Agreement as Follows:

Entities:

Novo Nordisk AS; ZymoGenetics, Inc.

Date:

2001

Size:

6KB total

Price:

$34

ID:

#332063

► Miscellany ► Agreements ► Misc. Agreements
► Biotech & Drugs ► Pharmaceutical Preparations
► Biotech & Drugs ► Biological Products

Start of Preview

{SEQUENCE}25

{FILENAME}dex1020.txt

{DESCRIPTION}AMENDED RESTATED HUMAN ANALOGUES LETTER AGMT

{TEXT}

{PAGE}



                                                                   EXHIBIT 10.20



 Amended and Restated Human Glucagon, Analogues of Human Glucagon, Analogs of

                        Human Insulin Letter Agreement



WHEREAS, ZGI, formerly an indirectly wholly owned subsidiary of NN, is engaged

generally in the research and development of biopharmaceutical products;



WHEREAS, NN and ZGI have settled NN's ongoing royalty obligation under this

Agreement for product known as NovoRapid(R), a human insulin analogue, pursuant

to a License Agreement having an effective date of September 28, 2000; and



WHEREAS, NN and ZGI wish to clarify the scope of this Agreement by deleting

analogues of human insulin therefrom;



NOW, THEREFORE, AS OF SEPTEMBER 28, 2000, THE PARTIES AGREE TO RESTATE THEIR

AGREEMENT AS FOLLOWS:



Pursuant to Section 6 of the Agreement dated August 6, 1982, between

ZymoGenetics, Inc. (formerly Zymos Corporation) and Novo Industri A/S (the

"Agreement") and with reference to our discussions at Novo on January 22, 1987,

we write to confirm the Agreement of ZymoGenetics, Inc. to the following terms

and conditions:



     1.  ZymoGenetics, Inc. ("ZYMO") hereby grants to Novo Industri A/S ("NOVO")

     a perpetual, exclusive, irrevocable, worldwide license (with the right to

     sublicense) to manufacture, have manufactured, use and sell Human Glucagon

     and Analogues of Human Glucagon through the use of Insulin Organisms,

     Technical Information and/or any Patents, the terms "Insulin Organisms",

     "Technical Information" and "Patents", having in this document the same

     meanings as in the Agreement.



     2.  In consideration of receiving the aforesaid license, NOVO shall make

     payments to ZYMO as set forth below:



         (a)  Definitions:



              (i)   "Participation Year" shall mean each successive twelve (12)

                    month period commencing on the date of the First Commercial

                    Sale;



              (ii)  "Net Sales" shall gross revenues to the NOVO Group from the

                    sale of Glucagon and/or Analogues of Glucagon produced

                    through the use of Insulin Organisms, Technical Information

                    and/or Patents under this license realized in each

                    participation Year less:



                       -  insurance and delivery charges paid or allowed by the

                       NOVO Group;

End of Preview

Home Intelligence Services Subscriptions News About Us